focus -WSS

focus

author：hotspot 2025-09-03 03:32:54 - browse：365

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： A Greenpeace activist is fined for crash

focus

WSS

Diversify hospital leadership teams to protect BIPOC patient health

Vermont grapples with historic flooding as more rainstorms head for Northeast

The new shift in health care is toward less care

Inflation cooled significantly in June, bringing price hikes close to normal levels

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Just how powerful is the placebo effect?

focus

focus

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

United colonoscopy coverage change 'may cost lives,' doctors say

Blinken talks high

State Dept. review finds Biden bears some blame for Afghanistan failures

UCSF medical school apologizes for unethical prisoner experiments

Dobbs anniversary: the lost opportunity of abortion as health care

FDA approves potent Eli Lilly obesity drug, Zepbound

In age of alternative facts, a scholarly course on calling out crap

Inflation cooled significantly in June, bringing price hikes close to normal levels

explore

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Free speech concerns arise in wake of journal editor Eisen's firing

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Abortion clinic in Cancun will cater to Americans

White House calls on federal agencies to crack down on AI abuses

leisure time

hotspot

focus

focus